Clinical Trial Update: A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema [Phase 1, Phase 2]

View source ↗

Summary

A dose-ranging study of OPT-302 in combination with aflibercept for persistent diabetic macular edema has completed (Phase 1/Phase 2) with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)
• OPT-302

Snippet

Sponsor: Opthea Limited | Conditions: Diabetic Macular Edema | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-22